Mankind Pharma Limited — PPTs, 31-07-2025: Investor Presentation

**Financial Highlights:**

Q1 FY26 revenue grew 24.5% YoY to 3,570 Cr. EBITDA reached 850 Cr (+25.8% YoY) with a 23.8% margin. Profit after tax was 445 Cr. Net debt stood at 5,249 Cr. Cash flow from operations converted 99% of EBITDA. An interim dividend was approved.

**Strategic Initiatives & Growth Drivers:**

Chronic segments outpaced IPM, driving strong volume growth. Strategy focuses on expanding super-specialty via BSV integration and in-licensing. R&D investment targets high-entry barrier products, alongside boosting consumer healthcare penetration.

**Business Developments:**

BSV consolidation boosted revenue, especially exports. Key Consumer Healthcare brands saw strong secondary sales. New product rollouts included Epic ThinX, Nimulid in CHC, and a new US market launch.

**Market Position & Competitive Advantage:**

Maintained #1 prescription rank for eight years and #2 by volume in the Indian pharma market, growing overall market share to 4.9%. Holds leading positions in key therapy areas and has four #1 ranked consumer healthcare brands.

**Investor Implications:**

Strong top-line and EBITDA growth highlights solid business and strategic acquisitions. High cash conversion signals efficiency. The shift towards high-growth specialty segments indicates positive long-term growth potential.